Across TCGA pan-cancer cohorts, OGN Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OGN data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OGN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OGN expression acts as an unfavorable survival marker.
LIHC, LUSC, and UCEC are the cancer types where OGN Mutation most reproducibly stratifies survival.